Literature DB >> 16995865

Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients.

Yu Zicheng1, Zhou Peijun, Xu Da, Wang Xianghui, Chen Hongzhuan.   

Abstract

AIMS: To characterize the pharmacokinetics of mycophenolic acid (MPA) in Chinese renal transplant patients.
METHODS: Thirty-one renal transplant patients (17 male, 14 female) receiving mycophenolate mofetil (MMF) 1.0 g twice daily were included in this study. A pharmacokinetic study was performed during an interval in dosing after steady state had been reached within 2 months after transplantation. The plasma MPA concentration were measured by high-performance liquid chromatography (HPLC) at 0.5, 1, 1.5, 2, 4, 6, 8, 10 and 12 h after the administration of a single dose. Pharmacokinetic parameters were calculated with 3P97 software. SAS software was used for statistical analysis. Multiple linear regression analysis was used to determine limited sampling approaches.
RESULTS: The mean peak plasma concentration (C(max)) and area under the concentration-time curve (AUC(0-12)) were 19.67 +/- 8.21 microg ml(-1) and 52.16 +/- 12.50 microg h ml(-1), but there was large variability in these pharmacokinetic parameters. Regression analysis between each plasma concentration and AUC for the limited sampling strategy of MMF therapeutic drug monitoring demonstrated that each of the concentrations at 0.5, 1, 4 and 10 h was positively correlated with AUC (r = 0.60, P = 0.0004; r = 0.60, P = 0.0003; r = 0.61, P = 0.0003; r = 0.64, P = 0.0001, respectively). The combined use of these four samples explained over 90% of the variance in the total (nine-point) AUC(0-12). A formula was obtained for the assessment of MPA AUC based on four samples: MPA AUC = 12.61 + 0.37 x C(0.5) + 0.49 x C(1) + 3.22 x C(4) + 8.17 x C(10).
CONCLUSIONS: Chinese renal transplant patients had higher median AUCs than caucasians and African-Americans. As in other studies, there was large interindividual variability. A limited four-point AUC was in good agreement with the 12-h AUC and provided the basis of a predictive formula.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16995865      PMCID: PMC1885158          DOI: 10.1111/j.1365-2125.2006.02626.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients.

Authors:  P J Smak Gregoor; C J Hesse; T van Gelder; B J van der Mast; J N IJzermans; N M van Besouw; W Weimar
Journal:  Transplant Proc       Date:  1998-06       Impact factor: 1.066

Review 2.  Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients.

Authors:  L M Shaw; M Korecka; D DeNofrio; K L Brayman
Journal:  Clin Biochem       Date:  2001-02       Impact factor: 3.281

Review 3.  Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

Authors:  M Oellerich; M Shipkova; E Schütz; E Wieland; L Weber; B Tönshoff; V W Armstrong
Journal:  Ther Drug Monit       Date:  2000-02       Impact factor: 3.681

Review 4.  Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation.

Authors:  L M Shaw; B Kaplan; D DeNofrio; M Korecka; K L Brayman
Journal:  Ther Drug Monit       Date:  2000-02       Impact factor: 3.681

5.  Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study.

Authors:  P J Smak Gregoor; T van Gelder; C J Hesse; B J van der Mast; N M van Besouw; W Weimar
Journal:  Nephrol Dial Transplant       Date:  1999-03       Impact factor: 5.992

6.  Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.

Authors:  M Mourad; J Malaise; D Chaib Eddour; M De Meyer; J König; R Schepers; J P Squifflet; P Wallemacq
Journal:  Clin Chem       Date:  2001-01       Impact factor: 8.327

7.  Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.

Authors: 
Journal:  Lancet       Date:  1995-05-27       Impact factor: 79.321

8.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

Authors: 
Journal:  Transplantation       Date:  1996-04-15       Impact factor: 4.939

Review 9.  Mechanism of action of mycophenolate mofetil.

Authors:  J T Ransom
Journal:  Ther Drug Monit       Date:  1995-12       Impact factor: 3.681

10.  Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients.

Authors:  R Bullingham; J Shah; R Goldblum; M Schiff
Journal:  Br J Clin Pharmacol       Date:  1996-06       Impact factor: 4.335

View more
  6 in total

1.  Limited sampling strategy models for estimating the AUC of gliclazide in Chinese healthy volunteers.

Authors:  Ji-Han Huang; Kun Wang; Xiao-Hui Huang; Ying-Chun He; Lu-Jin Li; Yu-Cheng Sheng; Juan Yang; Qing-Shan Zheng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-05-26       Impact factor: 2.441

2.  Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients.

Authors:  Prasanna K Subbanna; C G Prasanna; Bhagwat K Gunale
Journal:  Br J Clin Pharmacol       Date:  2007-04-10       Impact factor: 4.335

3.  Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients.

Authors:  Zi-Cheng Yu; Pei-Jun Zhou; Xiang-Hui Wang; Bressolle Françoise; Da Xu; Wei-Xia Zhang; Bing Chen
Journal:  Acta Pharmacol Sin       Date:  2017-08-24       Impact factor: 6.150

Review 4.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

5.  A Systematic Review of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid Area Under the Concentration-Time Curve Estimation.

Authors:  Joanna Sobiak; Matylda Resztak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-09-04       Impact factor: 2.441

6.  Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients.

Authors:  Changcheng Sheng; Qun Zhao; Wanjie Niu; Xiaoyan Qiu; Ming Zhang; Zheng Jiao
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.